Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06179160 ↗
- Recruiting
- Incyte Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Solid Tumors
- Interventions
- INCB161734; Cetuximab; Retifanlimab; GEMNabP; mFOLFIRINOX; FOLFOX; FOLFIRI; INCA33890
- Arms
- Part 1a: Dose Escalation monotherapy · Experimental
- Part 1b: Dose Expansion monotherapy · Experimental
- Part 1c: Pharmacodynamic cohort · Experimental
- Part 2a: Dose Escalation combination · Experimental
- Part 2b: Dose Expansion combination · Experimental
- Part 1d: Food-Effect · Experimental
- Enrollment
- 710 (estimated)
- Primary outcomes
- Number of participants with Dose Limiting Toxicities (DLTs)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)
- Number of participants with TEAEs leading to dose modification or discontinuation
- Sponsor
- Incyte Corporation
- Start
- Jan 4, 2024
- Primary completion
- Jan 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06179160 · updated Jul 22, 2026